EGFR and non-small cell lung carcinoma: In the Chinese ADJUVANT/CTONG1104 trial, adjuvant treatment with gefitinib significantly improved disease-free survival compared to chemotherapy with cisplatin and vinorelbine in patients with completely resected, EGFR-mutated, stage II to IIIA NSCLC (28.7 vs. 18.0 months; hazard ratio, 0.60; 95% CI, 0.42–0.87; P = 0.005) (11).